Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 20, 2019
TickeronGET DAILY SIGNALS
Three different biotech ETFs, three bearish signals with high confidence

Three different biotech ETFs, three bearish signals with high confidence

The biotech sector has been trending lower for the last five months, but has seen a bit of a rally over the last few weeks as investors appear to be making a shift from growth stocks to value stocks. Because of this rotation, many stocks in the sector are in overbought territory, at least on the daily charts. When I ran my nightly scans on Thursday night, I found three different biotech ETFs on my bearish scan and then I found that all three had seen bearish signals generated by the Tickeron Trend Prediction Engine.

The iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), the Direxion Daily S&P Biotech Bull 3x Shares (AMEX: LABU), and the SPDR S&P Biotech ETF (NYSE: XBI) are the three ETFs appearing on my bearish list.

Let’s look at each one individually. The IBB has been trending lower since early April and a downward sloped trend channel has formed in the last five months. The fund just hit the upper rail of the channel and that upper rail is in the same vicinity as the 50-day moving average.

The daily stochastic readings are in overbought territory and made a bearish crossover on September 19. The bearish signal from the Tickeron Trend Prediction Engine came on September 17. The signal shows a confidence level of 71% and it shows that 85% of past predictions on the IBB have been successful. The signal calls for a decline of at least 4% within the next month.

In addition to bearish signal from Tickeron, the technical analysis overview shows that the price moved below its 50-day Moving Average, which indicates a reversal from an uptrend to a downtrend. In 35 of 40 cases where IBB's price crossed below its 50-day Moving Average, its price fell further within the subsequent month. The odds of a continued downtrend are 88%.

Turning our attention to the leveraged LABU fund, we see that it peaked around the same time as the IBB. There trend line connecting the highs is cleaner than the upper rail of the channel on the IBB, but there isn’t a parallel lower rail that would form a channel.

Like we saw on the IBB chart, the daily stochastic readings for LABU are in overbought territory and made a bearish crossover on September 19. The Tickeron Trend Prediction Engine generated a bearish signal on September 17 as well. The signal for this ETF showed a confidence level of 80% while past predictions have been successful 97% of the time.

Additionally, the Tickeron Technical Analysis Overview shows that the higher Bollinger Band was broken. A price fall is expected as the ticker heads toward the middle band. In 37 of 38 cases where LABU's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

Finally, the chart for the XBI looks a little different from the other two ETFs. Yes, the fund peaked in April, but it has seen a trend channel form over the last three months and it just hit the upper rail of the channel this week. Like the IBB channel, the upper rail of the XBI channel is in close proximity to the 50-day moving average.

As we saw with the other two, the stochastic readings are in overbought territory and made a bearish crossover, and we have the bearish signal from Tickeron on September 17. The signal for the XBI showed a confidence level of 75% and past predictions were successful 90% of the time.

For the XBI, there were several other bearish factors on the technical analysis overview. First, the fund moved above its higher Bollinger Band on September 11, 2019. This price move signals that XBI may fall back below the higher band and head toward the middle band. In 39 of 43 cases where XBI's price broke its higher Bollinger Band, its price dropped further during the following month. The odds of a continued downtrend are 90%.

On September 12, the 50-day moving average crossed below its 200-day moving average and that indicates a sell signal, due to the trend repositioning lower. In 3 of 3 cases where XBI's 50-day moving average crossed below its 200-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 90%.

And like we saw on the IBB, the XBI saw its price drop below the 50-day moving average, which indicates a reversal from an uptrend to a downtrend. In 36 of 42 cases where XBI's price crossed below its 50-day moving average, its price fell further within the subsequent month. The odds of a continued downtrend are 86%.

Related Ticker: IBB

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for IBB turns positive, indicating new upward trend

IBB saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 80 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for IBB just turned positive on October 20, 2026. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.

IBB moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.

Following a +2.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 277 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

IBB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBB entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF (IBB) ETF is 8B. The market cap for tickers in the group ranges from 29.76M to 251.94B. AMGN holds the highest valuation in this group at 251.94B. The lowest valued company is AARD at 29.76M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 5%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was 30%. REPL experienced the highest price growth at 54%, while BCAX experienced the biggest fall at -47%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 23%. For the same stocks of the ETF, the average monthly volume growth was -24% and the average quarterly volume growth was -12%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 47
Price Growth Rating: 55
SMR Rating: 87
Profit Risk Rating: 85
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
415-670-2000
Web
www.ishares.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
Three different biotech ETFs, three bearish signals with high confidence